AR062950A1 - Compuestos tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen - Google Patents

Compuestos tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Info

Publication number
AR062950A1
AR062950A1 ARP070104197A ARP070104197A AR062950A1 AR 062950 A1 AR062950 A1 AR 062950A1 AR P070104197 A ARP070104197 A AR P070104197A AR P070104197 A ARP070104197 A AR P070104197A AR 062950 A1 AR062950 A1 AR 062950A1
Authority
AR
Argentina
Prior art keywords
compounds
tetraciclic
pharmaceutical compositions
compositions containing
preparation procedure
Prior art date
Application number
ARP070104197A
Other languages
English (en)
Inventor
Jean-Louis Peglion
Christophe Poitevin
Mark Millan
Mauricette Brocco
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR062950A1 publication Critical patent/AR062950A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Compuestos de la formula 1, de configuracion relativa trans: en la que: X representa un átomo de oxigeno o un grupo NR2, Y representa un grupo elegido entre -CH2-, -(CH2)2- y -CH=CH-, R1 y R2, idénticos o diferentes, representando cada uno un átomo de hidrogeno o un grupo elegido entre alquilo, cicloalquilo y cicloalquilalquilo, bajo forma racémica o de isomeros opticos, así como sus sales de adicion con un ácido farmacéuticamente aceptable y sus hidratos. Composicion farmacéutica. Proceso. Medicamentos utiles para tratar enfermedades del sistema nervioso central en las que está implicado el sistema dopaminérgico como depresion, ansiedad, Alzheimer, Parkinson.
ARP070104197A 2006-09-26 2007-09-24 Compuestos tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen AR062950A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0608413A FR2906249B1 (fr) 2006-09-26 2006-09-26 Composes tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
AR062950A1 true AR062950A1 (es) 2008-12-17

Family

ID=37877016

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104197A AR062950A1 (es) 2006-09-26 2007-09-24 Compuestos tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Country Status (32)

Country Link
US (1) US7470683B2 (es)
EP (1) EP1905775B1 (es)
JP (1) JP2008100995A (es)
KR (1) KR100934315B1 (es)
CN (1) CN101153043B (es)
AR (1) AR062950A1 (es)
AT (1) ATE480544T1 (es)
AU (1) AU2007219281A1 (es)
BR (1) BRPI0703655A2 (es)
CA (1) CA2603274C (es)
CY (1) CY1110799T1 (es)
DE (1) DE602007009004D1 (es)
DK (1) DK1905775T3 (es)
EA (1) EA013406B1 (es)
ES (1) ES2351945T3 (es)
FR (1) FR2906249B1 (es)
GE (1) GEP20104877B (es)
HK (1) HK1119163A1 (es)
HR (1) HRP20100605T1 (es)
MA (1) MA29371B1 (es)
MX (1) MX2007011524A (es)
MY (1) MY142517A (es)
NO (1) NO20074889L (es)
NZ (1) NZ561905A (es)
PL (1) PL1905775T3 (es)
PT (1) PT1905775E (es)
RS (1) RS51418B (es)
SG (1) SG141382A1 (es)
SI (1) SI1905775T1 (es)
UA (1) UA96125C2 (es)
WO (1) WO2008037888A2 (es)
ZA (1) ZA200708215B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1204745A (en) * 1981-11-20 1986-05-20 Merck Co. Hexahydronaphth (1,2-b) -1,4 -oxazines
US4420480A (en) * 1981-11-20 1983-12-13 Merck & Co., Inc. Hexahydronaphth[1,2-b]-1,4-oxazines
FR2721027B1 (fr) 1994-06-08 1996-07-19 Adir Nouveaux dérivés tétracycliques de la 1,4-oxazine, leur procédé de préparation et les compositions pharmaceutiques les contenant.
FR2741074B1 (fr) 1995-11-09 1997-12-19 Adir Nouveaux composes tetracycliques de la 1,4-oxazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2767825A1 (fr) 1997-09-01 1999-02-26 Adir Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2845994B1 (fr) * 2002-10-18 2006-05-19 Servier Lab Nouveaux derives de benzo[e][1,4]oxazino[3,2-g]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CA2603274C (fr) 2010-08-31
US20080076765A1 (en) 2008-03-27
GEP20104877B (en) 2010-01-11
US7470683B2 (en) 2008-12-30
PL1905775T3 (pl) 2011-03-31
ZA200708215B (en) 2008-09-25
EA013406B1 (ru) 2010-04-30
CN101153043A (zh) 2008-04-02
JP2008100995A (ja) 2008-05-01
RS51418B (en) 2011-02-28
UA96125C2 (ru) 2011-10-10
KR100934315B1 (ko) 2009-12-29
WO2008037888A3 (fr) 2008-06-12
ES2351945T3 (es) 2011-02-14
EA200701807A1 (ru) 2008-04-28
CN101153043B (zh) 2011-01-19
MA29371B1 (fr) 2008-04-01
FR2906249A1 (fr) 2008-03-28
EP1905775B1 (fr) 2010-09-08
KR20080028316A (ko) 2008-03-31
CA2603274A1 (fr) 2008-03-26
CY1110799T1 (el) 2015-06-10
HK1119163A1 (en) 2009-02-27
PT1905775E (pt) 2010-11-17
SI1905775T1 (sl) 2010-10-29
BRPI0703655A2 (pt) 2009-05-19
NO20074889L (no) 2008-03-27
NZ561905A (en) 2009-01-31
ATE480544T1 (de) 2010-09-15
MY142517A (en) 2010-12-15
EP1905775A1 (fr) 2008-04-02
FR2906249B1 (fr) 2008-12-19
DE602007009004D1 (de) 2010-10-21
WO2008037888A2 (fr) 2008-04-03
SG141382A1 (en) 2008-04-28
AU2007219281A1 (en) 2008-04-10
HRP20100605T1 (hr) 2010-12-31
MX2007011524A (es) 2009-02-16
DK1905775T3 (da) 2010-12-06

Similar Documents

Publication Publication Date Title
AR111242A1 (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak
CL2018000036A1 (es) Derivados etinilo
PE20160126A1 (es) Derivados del bipirazol como inhibidores jak
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
UY29827A1 (es) 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
UY31608A1 (es) Derivados de carboxamidas n-azabicíclicas, su preparación y su aplicación en terapéutica
UY31606A1 (es) Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica
CL2013003731A1 (es) Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad.
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
AR074358A1 (es) Derivados de pirazina como inhibidores de la fosfodiesterasa 10
AR094225A1 (es) Peptidos como agonistas de oxitocina
AR072819A1 (es) Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
NI201300072A (es) Derivados de heteroarilo como moduladores nachr alfa 7
PH12016502251A1 (en) Peptides as oxytocin agonists
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR099047A1 (es) Derivados etinilo
AR077960A1 (es) Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1)
AR096119A1 (es) Derivados 2-fenil- o 2- hetaril-imidazol[1,2-a]piridina
ECSP088257A (es) Derivados de amida
CU20160156A7 (es) Compuestos de isoquinolinas 2-sustituidas o sus análogos que poseen hasta cinco átomos de carbono sustituidos por nitrógeno,útiles como ligandos de dopamina d1
AR081908A1 (es) N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas
PH12016502232A1 (en) Peptides as oxytocin agonists

Legal Events

Date Code Title Description
FB Suspension of granting procedure